Stay updated with breaking news from 0fgen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Denny Jacob FibroGen shares sank 16% to $1.08 after it disclosed data from a study of pamrevlumab for the treatment of Duchenne muscular dystrophy didn't...
Capula Management Ltd purchased a new stake in shares of FibroGen, Inc. (NASDAQ:FGEN – Free Report) in the 1st quarter, Holdings Channel reports. The fund purchased 23,520 shares of the biopharmaceutical company’s stock, valued at approximately $439,000. A number of other institutional investors and hedge funds have also recently added to or reduced their stakes […]
FibroGen, Inc. (NASDAQ:FGEN – Free Report) – Investment analysts at William Blair lowered their Q3 2023 earnings estimates for shares of FibroGen in a research note issued on Tuesday, August 8th. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn ($0.72) per share for the quarter, down from their previous estimate […]
FibroGen (NASDAQ:FGEN – Get Free Report) was downgraded by analysts at Bank of America from a “neutral” rating to an “underperform” rating in a note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $2.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $4.00. Bank of […]
FibroGen, Inc. (NASDAQ:FGEN – Get Free Report) was the target of a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 7,870,000 shares, a growth of 18.9% from the June 15th total of 6,620,000 shares. Based on an average daily trading volume, of 2,160,000 shares, […]